Table 2.

Mean CDAI scores^a and mean change from baseline^a (missing data imputed using LOCF) through month 12 for golimumab-IV, dose-escalated infliximab^b, and non-dose-escalated infliximab among patients who were biologic-naïve or biologic-experienced

	Biologic-naïve patientsc				Biologic-experienced patients
	Golimumab-IV	Dose-escalated infliximab	Non-dose-escalated infliximab	Combined infliximab	Golimumab-IV	Dose-escalated infliximab	Non-dose-escalated infliximab	Combined infliximab
Patients, N	215	172	50	222	398	234	53	287
Baseline
Score	30.7 ± 21.3	30.7 ± 20.7	28.7 ± 21.8	30.3 ± 20.9	33.1 ± 20.6	34.3 ± 24.7	29.7 ± 20.2	33.5 ± 24.0
Month 6
Score	19.9 ± 23.6	20.3 ± 21.6	21.3 ± 23.1	20.6 ± 21.9	22.8 ± 21.0	25.7 ± 25.4	23.4 ± 24.2	25.3 ± 25.2
Change from baseline	– 10.8 ± 19.8	– 10.4 ± 18.9	– 7.4 ± 15.2	– 9.7 ± 18.2	– 10.3 ± 18.8	– 8.6 ± 21.7	– 6.3 ± 18.4	– 8.2 ± 21.1
Month 12
Score	19.7 ± 23.2	20.1 ± 21.7	20.8 ± 23.6	20.2 ± 22.1	22.1 ± 21.6	25.0 ± 25.6	23.0 ± 23.6	24.7 ± 25.2
Change from baseline	– 11.1 ± 19.8	– 10.7 ± 20.2	– 7.9 ± 17.4	– 10.0 ± 19.6	– 11.0 ± 18.4	– 9.3 ± 21.6	– 6.7 ± 18.0	– 8.9 ± 21.0

Data are presented as mean ± standard deviation

^aInverse probability of treatment weighted (IPTW)-adjusted

^bDose-escalated: Any patient with at least one normalized prescribed dose > baseline dose

^cPopulation included in major secondary endpoint analysis

CDAI clinical disease activity index, IV intravenous, LOCF last observation carried forward